Boston Partners
VVOS icon

Boston Partners’s Vivos Therapeutics VVOS Stock Holding History

Boston Partners’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,138
Closed -$51K – 767
2022
Q3 		$51K Sell
3,138
-1,828
-37% -$55.7K ﹤0.01% 710
2022
Q2 		$160K Sell
4,966
-528
-10% -$21.9K ﹤0.01% 678
2022
Q1 		$368K Buy
5,494
+1,173
+27% +$76.7K ﹤0.01% 639
2021
Q4 		$243K Buy
4,321
+2,455
+132% +$198K ﹤0.01% 659
2021
Q3 		$188K Buy
+1,866
New +$196K ﹤0.01% 655

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Boston Partners's VVOS Position: Q4 2022 in Review

Boston Partners sold out of Vivos Therapeutics (VVOS) in Q4 2022, closing a stake of 3,138 shares — an estimated $51K sold.

Boston Partners first reported a position in VVOS in Q3 2021 and held it in 5 quarters. The position peaked at $368K in Q1 2022. 27 funds tracked by Wall St. Rank hold VVOS as of Q4 2022.

  • Boston Partners reported no remaining Vivos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Boston Partners sold 3,138 Vivos Therapeutics shares in Q4 2022, an estimated $51K.
  • Boston Partners first reported a position in Vivos Therapeutics in Q3 2021 and held it in 5 quarters.
  • Boston Partners's Vivos Therapeutics position peaked at $368K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2022.

Based on Boston Partners's 13F filing for Q4 2022, filed 8 Feb 2023.